• Kengo Nagashima, Satoru Iwasa, Takako Yanai, Hironobu Hashimoto, Kenichi Suzuki, Fumiyoshi Ohyanagi, Yasuhiro Shimada, and Noboru Yamamoto.
• Clinical Research Center, Chiba University Hospital, Chiba.
• Jpn. J. Clin. Oncol. 2015 Feb 1; 45 (2): 229-31.

AbstractA randomized Phase II dose-finding trial comparing olanzapine 10 mg with olanzapine 5 mg for patients receiving highly emetogenic chemotherapy with cisplatin was started in June 2014. The purpose of the trial is to evaluate the efficacy and safety of the two olanzapine doses and to determine which is more promising as a test arm for comparison with the current standard antiemetic care (a combination of aprepitant, a 5-HT3 receptor antagonist and dexamethasone) in a subsequent Phase III trial. Patients receiving cisplatin-containing regimens will be randomized to the olanzapine 10 or 5 mg arm. A total of 150 patients will be accumulated from nine institutions over 2 years. The primary endpoint is complete response defined as no emetic episodes and no use of rescue medications in the delayed (24-120 h) phase. This trial has been registered at the UMIN Clinical Trials Registry as UMIN000014214.© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

35 keywords...

hide…